CalciMedica Obtains $32.5 Million Credit Facility to Advance Novel Therapies

CalciMedica Secures Up to $32.5 Million Credit Facility

On March 5, 2025, CalciMedica Inc. (NASDAQ: CALC), a clinical-stage biopharmaceutical firm centered on pioneering calcium release-activated calcium (CRAC) channel inhibition treatments for both acute and chronic inflammatory and immunologic diseases, announced the establishment of a new credit facility with Avenue Venture Opportunities Fund II, L.P., part of Avenue Capital Group. This credit line provides up to $32.5 million, a significant boost aimed at advancing CalciMedica's product pipeline.

The agreement entails an initial funding of $10 million available at the outset, with additional funding of up to $22.5 million contingent upon reaching certain milestones throughout the term of 3.5 years. Notably, no minimum cash requirements or financial covenants are stipulated in the agreement, affording CalciMedica the flexibility it needs during this critical development phase. With this financial backing, the company is positioned to sustain its operational endeavors into mid-2026, as stated by Rachel Leheny, Ph.D., the CEO of CalciMedica.

Dr. Leheny remarked, "This credit agreement provides CalciMedica with additional flexibility as we prepare for multiple critical milestones throughout 2025, including anticipated data from our Phase 2 KOURAGE trial of Auxora in patients with acute kidney injury and hypoxemia." The extension of their cash runway allows him to focus on pivotal developments, particularly the upcoming discussions with the FDA regarding the structure of a Phase 3 study for acute pancreatitis, after the results from the KOURAGE trial.

Chad Norman, Senior Portfolio Manager of Avenue Venture Opportunities Fund, expressed optimism about supporting CalciMedica’s mission to address significant unmet medical needs. He commended the potential of Auxora in treating acute inflammatory and immunologic conditions, reinforcing the expectation for considerable advancements in clinical trials.

About CalciMedica

CalciMedica specializes in the development of innovative therapies targeting the CRAC channels, which play a crucial role in regulating immune responses and mitigating tissue injury during inflammatory and immunological conditions. Their flagship product, Auxora™, has reported promising outcomes in several previous clinical trials.

The company is currently engaged in multiple clinical studies, including the KOURAGE trial evaluative of Auxora’s effectiveness for acute kidney injury, and a Phase 2 trial named CARDEA exploring treatment for patients with COVID pneumonia. Furthermore, CalciMedica is also running a Phase 1/2 trial (CRSPA) aimed at pediatric patients suffering from asparaginase-induced pancreatic toxicity (AIPT), with results anticipated in 2025.

Founded by a team of researchers from both Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, CalciMedica operates out of La Jolla, California. As the biopharmaceutical landscape continues to advance, the successful execution of the credit facility and forthcoming clinical milestones will be critical in shaping the future of treatment options available for patients suffering from severe inflammatory and immunologic diseases. For more detailed updates and information, CalciMedica’s developments can be tracked at www.calcimedica.com.

Navigating Future Challenges

This credit facility not only aids in bolstering CalciMedica’s existing projects but is also a critical stepping stone towards innovative treatment modalities for diseases currently lacking effective therapeutic options. Investors and stakeholders will be closely monitoring the upcoming trials and regulatory discussions that could redefine the company’s trajectory in the competitive biopharmaceutical arena.

Moreover, ongoing innovations in healthcare financing, such as the one facilitated by Avenue Capital, highlight the vital nature of strategic partnerships in fostering growth and development in the life sciences sector. As CalciMedica navigates these forthcoming challenges, the emphasis will remain on transparency and effective communication regarding clinical outcomes and strategic advancements in their therapeutic pipeline.

This development not only signals a promising horizon for CalciMedica but also reinforces the importance of sustained investment in biopharmaceutical innovation a crucial element in the quest to alleviate patient suffering in unmet medical needs.